Skip to main content
رجوع
CRNX logo

Crinetics Pharmaceuticals, Inc.

جودة البيانات: 100%
ذروة بيع
CRNX
NASDAQ Healthcare Biotechnology
KWD 34.37
▼ KWD 0.34 (-0.98%)
القيمة السوقية: 3.60B
نطاق اليوم
KWD 33.49 KWD 34.76
نطاق 52 أسبوعًا
KWD 24.10 KWD 57.99
حجم التداول
1,180,232
متوسط 50 يوم / 200 يوم
KWD 45.69 / KWD 39.68
الإغلاق السابق
KWD 34.71

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -7.7 0.3
P/B 3.6 2.9
ROE % -40.2 3.7
Net Margin % -6046.2 3.8
Rev Growth 5Y % 63.5 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 94.710 +175.6%
Low: KWD 67.000 High: KWD 143.000
ربحية السهم المستقبلية
-KWD 4.767
الإيرادات المقدّرة
62 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 4.932
KWD 3.441 – KWD 6.332
1.6 B 1
FY2029 KWD 0.954
KWD 0.666 – KWD 1.225
930 M 1
FY2028 -KWD 2.469
-KWD 3.717 – -KWD 0.985
420 M 5

النقاط الرئيسية

Revenue grew 63.46% annually over 5 years — strong growth
Debt/Equity of 0.05 — conservative balance sheet
Negative free cash flow of -383.68M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 577.25%
Capital intensive — 74.87% of revenue goes to capex

النمو

Revenue Growth (5Y)
63.46%
Revenue (1Y)640.71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-40.17%
ROIC-37.24%
Net Margin-6046.22%
Op. Margin-6714.77%

الأمان

Debt / Equity
0.05
Current Ratio12.32
Interest Coverage0.00

التقييم

P/E Ratio
-7.73
P/B Ratio3.63
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 640.71% Revenue Growth (3Y) 38.48%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 63.46% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7.70M Net Income (TTM) -465.32M
ROE -40.17% ROA -40.98%
Gross Margin 35.47% Operating Margin -6714.77%
Net Margin -6046.22% Free Cash Flow (TTM) -383.68M
ROIC -37.24% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.05 Current Ratio 12.32
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -7.73 P/B Ratio 3.63
P/S Ratio 467.61 PEG Ratio -0.28
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 3.60B Enterprise Value 3.55B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7.70M 1.04M 4.01M 4.74M 1.08M
Net Income -465.32M -298.41M -214.53M -163.92M -107.64M
EPS (Diluted) -4.95 -3.69 -3.69 -3.15 -2.80
Gross Profit 2.73M 1.04M 4.01M 4.74M 1.08M
Operating Income -516.77M -338.85M -222.61M -167.88M -107.70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.14B 1.43B 635.35M 352.18M 351.02M
Total Liabilities 143.41M 109.79M 96.25M 35.85M 19.07M
Shareholders' Equity 992.08M 1.32B 539.11M 316.33M 331.94M
Total Debt 48.54M 51.72M 51.73M 3.08M 3.07M
Cash & Equivalents 101.54M 264.55M 54.90M 32.67M 200.70M
Current Assets 1.05B 1.38B 574.15M 345.18M 344.72M
Current Liabilities 85.07M 59.68M 43.94M 27.72M 16.00M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#14 of 76
76

النشاط الأخير

دخل Capital Heavy Grower
Mar 24, 2026